Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Capecitabine (Xeloda®) in combination with oxaliplatin is recommended as an option for use within NHS Wales for the adjuvant treatment of patients following surgery of stage III (Dukes’ stage C) colon cancer. Capecitabine (Xeloda®) is not suitable for shared care within NHS Wales for the above indication. |
|||
|
|||
Medicine details |
|||
| Medicine name | capecitabine (Xeloda®) | ||
| Formulation | 150 mg and 500 mg film-coated tablet | ||
| Reference number | 412 | ||
| Indication | In combination with oxaliplatin for the adjuvant treatment of patients following surgery of stage III (Dukes’ stage C) colon cancer |
||
| Company | Roche Products Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Assessment type | Full | ||
| Status | Recommended | ||
| Advice number | 0511 | ||
| NMG meeting date | 10/03/2011 | ||
| AWMSG meeting date | 13/04/2011 | ||
| Ratification by Welsh Government | 01/09/2011 | ||
| Date of issue | 07/09/2011 | ||